Amphera B.V., a late clinical stage biotechnology company, develops MesoPher cell therapy for the treatment of cancer. Our lead indications are mesothelioma and pancreatic cancer.
MesoPher is comprised of autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour Associated Antigens. Several clinical studies with our lead product candidate MesoPher are ongoing.